Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162787 | 0.82 | BRD4 (0.36) | HRH4PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21174856 | 0.81 | MKNK1 (0.38) | PIK3CAPIK3CDPIK3CBPIK3CGDHFR | |
| SCHEMBL20162953 | 0.79 | PIK3CA (0.41) | PIK3CAPIK3R1 | |
| SCHEMBL16497095 | 0.77 | NUDT1 (0.43) | HRH4PIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL20162633 | 0.72 | PIK3CA (0.46) | PIK3CAMTORPIK3R1DHFRMAPT | |
| SCHEMBL20162866 | 0.70 | TNF (0.46) | PIK3CDPIK3CBPIK3CGNUDT1 | |
| SCHEMBL1946981 | 0.69 | IRAK4 (0.42) | BTKRAB9ANPC1PIK3CAMTOR | |
| SCHEMBL31262316 | 0.69 | RAB9A (0.46) | BTKHRH4RAB9ANPC1MTOR | |
| SCHEMBL14274543 | 0.68 | ADORA1 (0.51) | RAB9AALDH1A1 | |
| SCHEMBL27930287 | 0.68 | FGFR2 (0.54) | BTKHRH4RAB9ANPC1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| EP-3541390-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | BTK 629/4885HRH4 92/4885RAB9A 1235/4885 |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | BTK 629/4885HRH4 92/4885RAB9A 1235/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | BTK 629/4885HRH4 92/4885RAB9A 1235/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | BTK 704/4885HRH4 110/4885RAB9A 1482/4885 |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, P2RX1, P2RX5 | BTK 683/4885HRH4 92/4885RAB9A 1282/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | BTK 683/4885HRH4 92/4885RAB9A 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.